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Introduction 
Currently available chemotherapy is hampered 
by a lack in tumor specificity and resulting 
toxicity. Small and long-circulating liposomes 
can preferentially deliver chemotherapeutic 
drugs to tumors upon extravasation from tumor 
vasculature. Although clinically used 
liposomal formulations demonstrated 
significant reduction in toxicity, enhancement 
of therapeutic activity has not fully met 
expectations.  Tumors that stay in one spot and 
demonstrate limited growth is generally 
considered to be benign. When a tumor 
successfully spreads to other parts of the body 
and grows, invading and destroying other 
healthy tissues, it is said to have metastasized. 
This process itself is called metastasis, and the 
result is a serious condition that is very 
difficult to treat. In 2019, cancer claimed the 
lives of about 7.6 million people in the world. 
Low drug bioavailability from liposomal 
formulations and limited tumor accumulation 
remain major challenges to further improve 
therapeutic activity of liposomal 
chemotherapy. However, delivery systems 
have been developed to exploit a feature of 
tumor micro physiology often referred to as the 
„enhanced permeability and retention‟ effect. 
(1) This effect is a consequence of the 
dysregulated nature of tumor angiogenesis, 
which characteristically involves structural and 
physiologic defects leading to 
hyperpermeability. Macromolecular agents 
with highly restricted volumes of distribution 
and the capacity for greatly prolonged 
circulation will preferentially extravasate from 
these abnormal vessels and accumulate in 
tumor tissue. The figure 1 indicates the 
structure of liposomes.  
Liposomes, as carrier systems, have been 
explored more than any than other system as a 
result of their various forms. Phospholipid 
bilayers membranes can generate sphere 
structure with internal hydrophilic 
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compartment through introducing 
phospholipids in water solution; these 
structures are called liposomes. About four 
decades ago, Bangham and co-workers defined 
liposomes as vesicles with small size and 
spherical shapes that can be generated from 
phospholipids, cholesterols, non-toxic 
surfactants and even membrane protein. 
Investigations of this group resulted in 
regarding liposomes as delivery systems, 
which are characterized by carrying a variety 
of compounds in the core section. (2) These 
structures can encapsulate and deliver both 
hydrophilic and hydrophobic substances 
afflictively. Two important advantages of 
liposomes, in drug delivery of living 
organisms, are biocompatibility and 
biodegradability, which are due to lipid 
characteristics. (3) Different types of lipids and 
amphiphiles can act as liposomes. 
Furthermore, polymers can be used for the 
synthesis of polymerosomes as new drug/gene 
carriers. 
Types of liposomes and its preparation 
There are several approaches for preparation of 
liposomes, which include the use of 
mechanical procedures, organic solvents, or 
through the removal of detergent from 
phospholipid/detergent micelle mixtures. In 
liposome preparation, types and amounts of 
phospholipid, the ionic and charge properties 
of aqueous medium, as well as time 
hydrations, are important factors that 
determine the final liposome structure. 
 
 
Figure 1. Liposome structure 
 
Multilamellar vesicles preparation 
The Multilamellar vesicles are very simplest 
in production in comparison to all other 
liposomes.  
In this method, stages of liposome generation 
are used as organic solvent for dissolving of 
lipid and drying of the resulted mixture. 
Combination of lipids such as egg lecithin, 
cholesterol and phosphatidyl glycerol in a 
molar ratio of 0.9:1.0:0.1 are used 
respectively. Chloroform or a mixture of 
chloroform and methanol in a typical ratio of 
2:1 are used respectively. Firstly, each lipid 
component is dissolved in the organic solvent 
separately, followed by mixing in the suitable 
proportion with the other solubilized lipids to 
ensure and uniform distribution of the lipids 
in mixture. Afterwards, nitrogen stream is 
used to generate a film from the mixture in 
test tube. Also, in order to remove any last 
traces of organic solvent, the film of lipid is 
allowed to dry completely in an evacuated 
chamber for a minimum of 4-6 hours. (4) 
Unilamellar vesicles preparation  
The unilamellar vesicle is the most popular 
type of liposomes. Its liposome structure 
allows for an even distribution of trapped 
agents within a single internal aqueous 
compartment. There are several methods for 
preparation of these structures including 
ultrasonication, extrusion through 
polycarbonate filters, freeze-thawing, ethanol 
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injection, detergent method and preparation 
of sterile large unilamellar vesicles. Bhatia et 
al (2015) used mixture of different small 
unilamellar vesicles (SUVs) populations for 
obtain ternary GUV with uniform property. 
(5) 
Giant Unilamellar  
Liposomes Preparation There are many 
methods in the preparation of giant liposomes 
based on utilizing only distilled water, 
nonelectrolyte or zwitterions. There is an 
increase in attraction between membranes 
caused by the presence of ions imparting a net 
charge, and thereby inhibiting the separation 
of the membrane sheets during the 
rehydration and swelling process. Recently, 
researchers have demonstrated preparation of 
giant liposomes, using physiological strength 
buffers. There are several methods for 
preparation of these systems including 
electroformation, giant liposomes prepared in 
rapid preparation, using physiological buffer 
for preparation of giant unilamellar liposomes 
and osmotic shock technique. Also, 
Karamdad and coworkers (2015) used new 
method of a microfluidic for GUV 
preparation and mechanical characterization. 
(6) 
Drug Delivery System 
The art of drug delivery can be defined as the 
approach of physical, chemical and biological 
sciences to furnish physiological 
administration of therapeutic molecules for 
health benefits. (7) When the 
pharmacologically effective drugs 
administered for the treatment of disease 
endeavor physicochemical and physiological 
barriers at disease sites, their therapeutic 
potency is prominently abridged. Hence, 
improving the physicochemical properties of 
medicaments and overcoming the 
physiological barriers for the entry of drug to 
be delivered into the disease site for efficient 
therapeutic activity is one of the major 
concerns of the present day medicine. (8) The 
limitations of physiochemical and 
physiological properties finally hinder the 
therapeutic potential of the administered 
dosage forms that result in poor clinical 
performances in the treatment of diseases. 
These restrictions and shortcomings can be 
overcome by a controlled drug delivery 
system where the drug is delivered directly to 
the site of action capacitated to surpass the 
effects of physiochemical and physiological 
barriers, thereby, improving the efficiency of 
drug delivery. This advanced form of therapy 
is particularly important when there are 
conflicts between the doses, the amount of 
drug required for therapeutic effects and 
unwanted side effects. (9) 
Liposomes as Drug Delivery System 
Liposomes are spherical vesicles composed 
of lipid bilayer arranged around a central 
aqueous core. They can be composed of 
natural constituents such as phospholipids 
and may mimic naturally occurring cell 
membranes. Liposomes have the ability to 
incorporate lipophilic and amphiphilic drugs 
within their phospholipid membrane or they 
can encapsulate hydrophilic compounds 
within the aqueous core. Liposome 
formulations can therefore increase safety and 
efficiency in reaching the site of action. 
The applicability of drugs is always a 
compromise between their therapeutic effect 
and side effects. Like allother carrier systems, 
the use of liposomes in drug delivery has 
advantages and disadvantages. The 
amphiphilic character of the liposomes, with 
the hydrophobic bilayer and the hydrophilic 
inner core, enables solubilization or 
encapsulation of both hydrophobic and 
hydrophilic drugs. The most active drugs 
against breast cancer are currently the 
anthracyclines and taxanes (paclitaxel and 
docetaxel). (10) Strategies for the delivery of 
taxanes are under active investigation to 
increase tumor exposure and/or to reduce 
adverse effects such as neurotoxicity, edema, 
asthenia, and alopecia. (10,11) Other 
applications for delivery systems in breast 
cancer include approved chemotherapy drugs 
such as vinca alkaloids, platinums, and 
camptothecins. In each case, it is possible that 
delivery systems such as liposomes or 
polymers could improve pharmacokinetics, 
could increase tumor accumulation, and/or 
could reduce limiting toxicities. While 
delivery systems for standard anticancer 
compounds may increase their clinical utility, 
there is also intense interest in developing 
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delivery strategies for novel anticancer agents 
that cannot be used by themselves as drugs. 
Delivery systems can potentially overcome 
many common pharmacologic problems such 
as those involving solubility, in vivo stability, 
pharmacokinetics, tumor uptake, and toxicity. 
The increasing repertoire of sophisticated 
delivery systems may thus allow new classes 
of potent anticancer agents to reach clinical 
application. This includes not only drug 
delivery, but also liposome-derived systems 
for nucleic acid-based agents, such as 
antisense oligonucleotides and gene therapy 
constructs. (12) 
Along with their good solubilization power, a 
relatively easy preparation and a rich 
selection of physicochemical properties have 
made liposomes attractive drug carrier 
systems. Efficient drug delivery systems 
based on liposomes need to possess a large 
number of special qualities. First, good 
colloidal, chemical and biological stability is 
required. The fact that liposomes are 
nonequilibrium structures does not 
necessarily mean that they are unsuitable for 
drug delivery. On the contrary, a colloidally 
stable nonequilibrium structure is less 
sensitive to external changes than equilibrium 
structures, such as micelles. Hence, 
colloidally stable liposomes often work well 
in pharmaceutical applications. Biological 
stability includes control over the rate of 
clearance of liposomes from the circulatory 
system or compartments of the body, if the 
drug has been administered locally. The rate 
of clearance is dose dependent and varies 
according to the size and surface charge of 
the liposomes. Early studies using 
conventional liposomes revealed that the 
clearance was too rapid for an effective in 
vivo drug delivery. In contrast to a sustained 
release, liposomes also have to be able to 
release the encapsulated drug, which might 
not be as easy as it sounds, and, they should 
preferably also be targeted. (13) 
Liposomes in cancer therapy  
Liposomes are used for drug delivery in 
cancer therapy due to their unique properties. 
They have the distinct advantages of being 
non-toxic and degradable in the body because 
of their naturally occurring lipids as main 
content.  Liposomes have also a unique 
ability to entrap both hydrophilic and 
lipophilic drugs to its compartment and lead 
to a controlled release effect. Drug 
entrapment in the liposomes has also shown 
reduced drug toxicity due to minimized 
uptake in other tissues such as heart, kidneys 
and gut, beside their ability to protect the 
entrapped drugs from degradation in the 
blood stream. Their most important properties 
are the ability to accumulate in the tumors by 
passive targeting due to the enhanced 
permeability and retention effect (EPR). The 
EPR effect is due to the differences between 
the vasculature in tumors and healthy tissues. 
Because of the angiogenesis, the blood 
vessels in tumor are leakier and have less 
perfect cellular packing leading to bigger 
gaps between the cells. Furthermore, the 
lymphatic system which is responsible for 
removing substances such as liposomes or 
other nanoparticles from the tissues is 
marginally expressed compared to normal 
tissue. By utilizing the EPR effect, small 
liposomes (< 70 nm) are able to escape 
vasculature within tumors and accumulate 
there via passive targeting effect.  
Liposomes have been successfully used in 
cancer therapy. Although, the application of 
liposomes in the field of cancer therapeutics 
has been extensively studied and deserves a 
broad assessment but this is outside the scope 
of this review. However, the most successful 
applications of liposomes in cancer 
therapeutics are discussed here. A number of 
different liposomal formulations of anti-
cancer agents have been shown to deliver the 
drug at the site of solid tumors with minimum 
toxicity as compared to free drug. (14-16) 
Currently, there are a many products in the 
market and in clinical development for use as 
anti-cancer drug delivery vehicle. Doxil, a 
PEGylated liposomal formulation, is the first 
liposomal product that was approved by the 
FDA for the treatment of kaposi's sarcoma in 
AIDS patients (17-19). Doxil (US), or Caelyx 
(outside-US) is a PEGylated liposomal 
formulation encapsulating anticancer drug 
doxorubicin commercialized by Johnson & 
Johnson. In 2011, an imbalance between the 
demand and supply of Doxil was observed as 
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the manufacturing unit was shut down 
temporarily due to some quality control 
issues. (20,21) To address the Doxil shortage 
in USA, FDA allowed temporary importation 
of LipoDox. LipoDox is the same liposomal 
formulation as Doxil in USA and made in 
India by Sun Pharma and in 2013, FDA 
approved the first generic version of Doxil, 
made by Sun Pharma. 
Lipoplatin is the liposomal formulation of 
cisplatin designed by Regulon Inc. and 
currently, it is being evaluated in phase III 
clinical trial for the patients with non-small 
cell lung cancer. (22) Another liposomal 
formulation Stimuvax is designed as anti-
MUC1 cancer vaccine by Oncothyreon to 
treat non-small cell lung cancer and presently 
is in phase III clinical trial. (23-25). The 
thermo sensitive liposomal formulation of 
doxorubicin, called ThermoDox (Celsion) is 
under phase III clinical trial to treat the 
patients with primary hepatocellular 
carcinoma, in phase II for refractory chest 
wall breast cancer and colorectal liver 
metastasis. (26, 27) 
Conclusion  
In study of various literature and study work 
we found and concluded that liposomes as 
anticancer for use in targeted cancer therapy 
have solely been investigated in the pre-
clinical setting. Obtained results certainly 
provide a promise that in the future this drug 
carrier system could achieve more specific 
and less toxic clinical delivery of a wide 
variation of anticancer drugs in cancers such 
as glioblastoma multiform, where currently 
available therapy lacks efficiency. However, 
for liposome-based anticancer therapy to 
display maximal effect and minimal side 
effects, it requires identification of specific 
target molecules and appropriate drugs to be 
delivered. 
Liposomes have revolutionized cancer 
therapy by their broad clinical applications. 
Liposomes overcome the limitations of 
conventional chemotherapy by improving the 
bioavailability and stability of the drug 
molecules and minimizing side effects by 
site-specific targeted delivery of the drugs. 
Liposomes were the first nanotechnology-
based drug delivery systems approved for the 
clinical applications because of their 
biocompatibility and biodegradability like 
features. Some liposome-based drug delivery 
systems are already in the market and many 
more are undergoing research and clinical 
trials. So far, liposomes have established 
themselves in nanocarriers-based drug 
delivery systems as evident by the successful 
clinical applications of liposomal 
formulations in anti-cancer therapy. Thus, 
based on the molecular characteristics of the 
different cell populations within a specific 
tumor, Immuno-liposomes that target a highly 
expressed molecule and contain a drug of 
anticipated effect can be prepared specifically 
for the chosen target cell population. In the 
clinical setting, this allows application of 
highly “personalized”, multi targeted Immuno 
liposomes for the single patient. 
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